TY  - JOUR
PY  - 2020//
TI  - Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults
JO  - Drug and alcohol dependence
A1  - Peck, Kelly R.
A1  - Ochalek, Taylor A.
A1  - Badger, Gary J.
A1  - Sigmon, Stacey C.
SP  - e107879
EP  - e107879
VL  - 208
IS  - 
N2  - OBJECTIVE: Although opioid maintenance is a first-line approach for treating opioid use disorder (OUD), suboptimal treatment outcomes have been reported among emerging adults (EAs; 18-25 years of age). In this secondary analysis, we compared treatment outcomes between EAs and older adults (OAs; ≥ 26 years of age) receiving low-barrier, technology-assisted Interim Buprenorphine Treatment (IBT) during waitlist delays to comprehensive opioid maintenance treatment. <br><br>METHOD: Participants were 35 individuals with OUD who received IBT consisting of 12-weeks of buprenorphine maintenance with bi-monthly clinic visits and technology-assisted monitoring. At monthly follow-up assessments, participants completed staff-observed urinalysis, the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II), and Addiction Severity Index (ASI). <br><br>RESULTS: At study intake, EAs (n = 10) reported greater past-year intravenous drug use and greater employment, legal, and psychiatric severity (p's <.05) compared to OAs (n = 25). Despite these initial differences, there were no significant differences in the percentages of urine specimens testing negative for illicit opioids between EA and OA participants at Study Week 4 (90 % vs. 88 %, p =.99), Week 8 (80 % vs. 76 %, p =.99) or Week 12 (60 % vs. 68 %, p =.71). Relative to their older peers, EAs also demonstrated significantly greater improvements on the BAI, BDI-II, and ASI Employment and Legal subscales (p's <.05). <br><br>CONCLUSIONS: Despite presenting with greater past-year intravenous drug use and psychosocial severity relative to OAs, EAs responded favorably to the IBT intervention.<br><br>Copyright © 2020 Elsevier B.V. All rights reserved.<p />  <p>Language: en</p>
LA  - en
SN  - 0376-8716
UR  - http://dx.doi.org/10.1016/j.drugalcdep.2020.107879
ID  - ref1
ER  -